Transaction #33255 · Form 4 · 0001829126-26-011084
TRex Bio, Inc. · Conversion · Common Stock
TRex Bio, Inc. · Transacted October 13, 2026 · Filed October 13, 2026
What does this filing report?
An SEC Form 4 filing for TRex Bio, Inc. records a conversion involving Common Stock on October 13, 2026. The reported quantity was 53,892. The filing date is October 13, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- TRex Bio, Inc.
- Company CIK
- 0002139097
- Security type
- Non-derivative
- Acquisition type
- Conversion · Code C
- Quantity acquired
- 53,892
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 61,248
- Ownership description
- By SV Life Sciences Fund VI Strategic Partners, L.P.
- SEC acceptance time
- Oct 13, 2026, 4:30 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- SV Life Sciences Fund VI, L.P. ↗
10% owner
CIK 0001642251
- SVLSF VI, LLC ↗
10% owner
CIK 0001717728
- SV Life Sciences Fund VI (GP), L.P. ↗
10% owner
CIK 0001717730
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The shares are held directly by SV Life Sciences Fund VI, L.P. ("SV Fund VI"). SV Life Sciences Fund VI (GP), L.P. (the "GP LP") is the general partner of SV Fund VI, and SVLSF VI, LLC ("SVLSF") is the general partner of GP LP. Investment and voting decisions of SV Fund VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.
- F2
- The shares are held directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SV Strategic Partners VI"). GP LP is the general partner of SV Strategic Partners VI, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Strategic Partners VI are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership except to the extent of its pecuniary interest, and this report is not an admission of beneficial ownership for any other purpose.
- F3
- The shares are held directly by SV Trex Coinvestment, L.P. ("SV Coinvestment"). GP LP is the general partner of SV Coinvestment, and SVLSF is the general partner of GP LP. Investment and voting decisions of SV Coinvestment are made by the investment committee of SVLSF. Each of GP LP and SVLSF disclaims beneficial ownership and this report is not an admission of beneficial ownership for any other purpose.
- F4
- On October 13, 2026, 3.8649 shares of preferred stock automatically converted into one share of common stock upon the closing of the issuer's initial public offering, for no additional consideration. The preferred stock has no expiration date.
- F5
- Represents shares purchased by SV Fund VI in the issuer's initial public offering.
- F6
- Represents shares purchased by SV Strategic Partners VI in the issuer's initial public offering.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.